Volume 99, Issue 1 p. 72-81
State of the Art

Protease receptor antagonism to target blood platelet therapies

M Holinstat

M Holinstat

University of Michigan Medical School, Departments of Pharmacology and Internal Medicine, Ann Arbor, Michigan, USA

Search for more papers by this author
PF Bray

Corresponding Author

PF Bray

Thomas Jefferson University, The Cardeza Foundation for Hematologic Research and the Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania, USA

Correspondence: PF Bray ([email protected])Search for more papers by this author
First published: 26 October 2015
Citations: 8


Platelet activation and thrombus formation play a central role in ischemic vascular disease. Thrombin, an especially potent physiologic agonist mediating in vivo activation of platelets, acts via a unique family of G-protein-coupled receptors called protease-activated receptors (PARs) with a broad tissue expression. This review focuses on current antiplatelet therapies as well as innovative approaches to targeting PARs in patients with atherothrombotic vascular disease.